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Abstract
Background: The contribution of sex as an independent risk factor for cardiovascular disease still 
remains controversial. The present study investigated the impact of sex on long-term clinical outcomes 
in Korean acute myocardial infarction (AMI) patients with a history of current smoking on admission 
after drug-eluting stents (DESs).
Methods: A total of 12,565 AMI patients (male: n = 11,767 vs. female: n = 798) were enrolled. Major 
adverse cardiac events (MACEs) comprising all-cause death, recurrent myocardial infarction (Re-MI),  
and any repeat revascularization were the primary outcomes that were compared between the two 
groups. Probable or definite stent thrombosis (ST) was the secondary outcome.
Results: After adjustment, the early (30 days) cumulative incidences of MACEs (adjusted hazard 
ratio [aHR]: 1.457; 95% confidence interval [CI]: 1.021–2.216; p = 0.035) and all-cause death (aHR: 
1.699; 95% CI: 1.074–2.687; p = 0.023) were significantly higher in the female group than in the male 
group. At 2 years, the cumulative incidences of all-cause death (aHR: 1.561; 95% CI: 1.103–2.210;  
p = 0.012) and Re-MI (aHR: 1.800; 95% CI: 1.089–2.974; p = 0.022) were significantly higher in the 
female group than in the male group. However, the cumulative incidences of ST were similar between 
the two groups (aHR: 1.207; 95% CI: 0.583–2.497; p = 0.613).
Conclusions: The female group showed worse short-term and long-term clinical outcomes compared 
with the male group comprised of Korean AMI patients with a history of current smoking after success-
ful DES implantation. However, further studies are required to confirm these results. (Cardiol J)
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Introduction
As age increases, the incidence and mortal-
ity rates of cardiovascular disease (CVD) also 
increases. Moreover, other factors affecting the 
long-term prognosis of CVD are of utmost impor-
tance for public heath investigators and cardiolo-
gists. Previously, based on sex difference, a higher 
mortality rate of myocardial infarction (MI) was 
observed in women than in men [1, 2]. However, 
the contribution of sex as an independent risk fac-
tor for CVD still remains controversial. Proposed 
explanations for higher mortality rate among 
women are advanced age and increased incidence 
of diabetes mellitus (DM), chronic heart failure 
(HF), and hypertension prior to MI [3]. Cigarette 
smoking is an important correctable risk factor and 
a major causative factor of recurrent MI and death 
after percutaneous coronary intervention (PCI) [4]. 
According to a recent report, the estimated preva-
lence of cigarette smoking was not strongly associ-
ated with sex difference [5]. In 2012, the estimated 
prevalence rates of smokers were greater than 
40% among men and lower than 5% in women [5]. 
Additionally, controversy exists whether sex dif-
ference is associated with smoking and adverse 
cardiovascular clinical outcomes [6]. To date, the 
cumulative incidences of acute myocardial infarc-
tion (AMI) are increasing in South Korea [7]. In 
real-world practice, the use of bare-metal stent 
(BMS) is limited. Therefore, we investigated the 
impact of sex difference on the 2-year clinical 
outcomes in Korean AMI patients with a history 
of current smoking on admission who underwent 
successful PCI with drug-eluting stents (DESs).
Methods
Study design and population
This study was a nonrandomized, multicenter, 
observational retrospective cohort study, and the 
study population was obtained from the Korea AMI 
Registry (KAMIR). Detailed information about 
the KAMIR has already been published [7, 8]. 
A total of 20,174 AMI patients who were active 
smokers on admission between November 2005 
and June 2015 were evaluated. Patients with the 
following characteristics were excluded from the 
study: (1) patients who underwent fibrinolysis 
(n = 609, 3.0%), (2) patients who did not undergo PCI 
(n = 616, 3.1%), (3) patients with failed PCI (n = 415, 
2.1%), (4) patients who underwent coronary artery 
bypass graft (n = 55, 0.3%), (5) patients with BMS 
(n = 942, 4.7%), (6) patients with incomplete labo-
ratory results (n = 3562, 17.6%), and (7) patients 
who were lost to follow-up (n = 1410, 7.0%). Final-
ly, a total of 12,565 AMI patients who were active 
smokers at the time of admission who underwent 
successful PCI with DESs were enrolled. They 
were grouped based on their sex; male (n = 11,767, 
93.6%) and female groups (n = 798, 6.4%) (Fig. 1, 
Table 1). This study was conducted according to 
the ethical guidelines of the 1975 Declaration of 
Helsinki. This study protocol was approved by 
the ethics committee of each participating center, 
and informed consent was obtained from all indi-
vidual participants prior to their enrollment. All 
12,565 AMI patients completed a 2-year clinical 
follow-up, and were tracked the enrolled patients 
via direct interviews, telephone contact, and chart 
reviews [9]. All clinical events were evaluated by 
an independent event adjudication committee. The 
event adjudication processes were described in 
a previous publication established by the KAMIR 
investigators [8].
Percutaneous coronary intervention  
procedure and medical treatment
Coronary angiography and PCI were per-
formed as described before [10]. Before PCI, 200 
to 300 mg of acetylsalicylic acid (ASA) and 300 to 
600 mg of clopidogrel was administered. If pos-
sible, 180 mg of ticagrelor or 60 mg of prasugrel 
was administered. After discharge, 100 to 200 mg/ 
/day of ASA was continued indefinitely, and 75 mg/ 
/day of clopidogrel was maintained for at least 12 
Figure 1. Flow chart; AMI — acute myocardial infarc-
tion;  BMS — bare-metal stent; CABG — coronary artery 
bypass grafting; PCI — percutaneous coronary inter-
vention.
Korea AMI Registry (November 2005 to June 2015):
20,174 AMI patients with a history of current smoking on admission
Exclusion criteria
Fibrynolysis (n = 609)
DId not undergo PCI (n = 616)
Failed PCI (n = 415)
CABG (n = 55)
BMS deployment (n = 942)
Incomplete laboratory results (n = 3562)
Lost to follow-up (n = 1410)
Final study population:
12,565 AMI patients who has been current smokers and underwent
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Table 1. Baseline clinical, laboratory, and procedural characteristics.
Variables Male (n = 11,767) Female (n = 798) P SD
Age [years] 56.7 ± 11.2 68.3 ± 11.5 < 0.001 1.21
LVEF [%] 52.6 ± 11.0 52.5 ± 11.8 0.724 –0.09
LVEF < 40% 1256 (10.7%) 96 (12.6%) 0.232 0.70
BMI [kg/m2] 24.3 ± 3.1 23.3 ±3.6 <0.001 –2.98
SBP [mmHg] 130.0 ± 27.2 128.4 ± 28.9 0.103 –0.57
DBP [mmHg] 80.2 ± 16.6 77.5 ± 17.2 < 0.001 –1.60
STEMI 7480 (63.6%) 468 (58.6%) 0.005 –1.33
Primary PCI 6919 (92.5%) 429 (91.7%) 0.508 –0.33
NSTEMI 4287 (36.4%) 330 (41.4%) 0.005 1.34
PCI within 24 h 3342 (78.0%) 250 (75.8%) 0.354 –0.66
Hypertension 4237 (36.3%) 410 (51.4%) < 0.001 3.99
Diabetes mellitus 2510 (21.3%) 216 (27.1%) < 0.001 1.70
Dyslipidemia 1273 (10.8%) 80 (10.0%) 0.484 –0.31
Previous MI 338 (2.9%) 15 (1.9%) 0.101 –0.60
Previous PCI 476 (4.0%) 29 (3.6%) 0.567 –0.22
Previous CABG 27 (0.2%) 2 (0.3%) 0.904 0.07
Previous CVA 431 (3.7%) 51 (6.4%) < 0.001 1.23
Previous HF 59 (0.5%) 11 (1.4%) 0.001 0.58
Cardiogenic shock 454 (3.9%) 48 (6.0%) 0.003 0.97
CPR on admission 364 (3.1%) 27 (3.4%) 0.648 0.16
CK-MB [mg/dL] 152.9 ± 149.4 140.4 ± 173.1 0.177 –0.77
Troponin-I [ng/mL] 52.1 ± 91.4 44.0 ± 41.5 0.473 –1.14
NT-ProBNP [pg/mL] 1042.6 ± 1119.8 3008.0 ± 3822.9 < 0.001 6.98
hs-CRP [mg/dL] 9.4 ± 51.0 8.6 ± 39.9 0.716 –0.17
Serum creatinine [mg/L] 1.1 ± 1.3 0.9 ± 0.6 0.001 –1.85
Total cholesterol [mg/dL] 187.4 ± 43.6 195.9 ± 48.2 < 0.001 1.98
Triglyceride [mg/L] 151.2 ± 129.5 137.2 ± 106.7 0.003 –1.18
HDL cholesterol [mg/L] 42.7 ± 18.5 45.0 ± 11.8 0.001 1.48
LDL cholesterol [mg/L] 119.5 ± 41.1 125.0 ± 42.7 < 0.001 1.31
Discharge medications:
Acetylsalicylic acid 11410 (97.0%) 757 (94.9%) 0.001 –1.02
Clopidogrel 10473 (89.0%) 744 (93.2%) < 0.001 1.88
Ticagrelor 648 (5.5%) 24 (3.0%) 0.002 –1.38
Prasugrel 485 (4.1%) 16 (2.0%) 0.003 –1.25
Cilostazole 2798 (23.8%) 194 (24.3%) 0.733 0.15
BBs 9563 (81.3%) 594 (74.4%) < 0.001 –2.05
ACEIs 7207 (61.2%) 464 (58.1%) 0.082 –0.82
ARBs 2465 (20.9%) 160 (20.1%) 0.546 -0.25
CCBs 674 (5.7%) 56 (7.0%) 0.132 0.58
Lipid lowering agents 9669 (82.2%) 624 (78.2%) 0.005 -1.24
Angiographic and procedural characteristics
Infarct-related artery
Left main 174 (1.5%) 10 (1.3%) 0.608 –0.13
Left anterior descending 5765 (48.9%) 324 (40.6%) < 0.001 –2.23
Left circumflex 2033 (17.3%) 133 (16.6%) 0.659 –0.24
Right coronary artery 3795 (32.3%) 331 (41.5%) < 0.001 2.46
Æ
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months. Triple antiplatelet therapy (TAPT) (100 
mg of cilostazol [Pletaal®, Otsuka Pharmaceuti-
cal Co., Tokyo, Japan] twice a day added on a dual 
antiplatelet therapy) was left to the discretion of 
the individual operators [9].
Study definitions and clinical outcomes
Acute myocardial infarction was defined ac-
cording to the current guidelines [11, 12]. Current 
smoking was defined as cigarette smoking within 
1 year before the index PCI [9, 13]. Smoking history 
was assessed based on patient medical records. In 
this study, the occurrence of major adverse cardiac 
events (MACEs) was the primary endpoint. MACEs 
comprised all-cause death, recurrent myocardial 
infarction (Re-MI), and any repeat revasculariza-
tion during a 2-year follow-up period. All-cause 
death was classified as a cardiac death (CD) or 
a non-CD. Re-MI was defined as the reoccurrence 
of AMI [14]. Any repeat revascularization com-
prised target lesion revascularization (TLR), target 
vessel revascularization (TVR), and non-TVR. 
Previously, the definitions of TLR, TVR, and non-
TVR were published [14]. The secondary endpoint, 
the cumulative incidences of definite or probable 
stent thrombosis (ST), was defined according to 
the onset of this event as follows: acute (0–24 h), 
subacute (24 h–30 days), late (30 days–1 year), and 
very late (> 1 year) [14, 15].
Statistical analyses
The Statistical Package for the Social Sciences 
software version 20 (International Business Ma-
chines Corporation, Armonk, NY, USA) was used 
during the statistical analyses of this study. In case 
of continuous variables, differences between the 
Table 1 (cont.). Baseline clinical, laboratory, and procedural characteristics.
Variables Male (n = 11,767) Female (n = 798) P SD
Treated vessel:
Left main 249 (2.1%) 18 (2.3%) 0.791 0.12
Left anterior descending 6655 (56.6%) 403 (50.5%) 0.001 –1.61
Left circumflex 2956 (25.1%) 190 (23.8%) 0.408 –0.40
Right coronary artery 4530 (38.5%) 377 (47.2%) < 0.001 2.30
ACC/AHA lesion type:
Type B1 1801 (15.3%) 126 (15.8%) 0.714 0.17
Type B2 3554 (30.2%) 215 (26.9%) 0.052 –0.96
Type C 5148 (43.7%) 379 (47.5%) 0.039 1.00
Extent of coronary artery disease:
1-vessel 5962 (50.7%) 369 (46.2%) 0.016 –1.19
2-vessel 3695 (31.4%) 233 (29.2%) 0.293 -0.63
≥ 3-vessel 2110 (17.9%) 196 (24.6%) < 0.001 2.01
Drug-eluting stents:
SES 2155 (18.3%) 168 (21.1%) 0.054 0.88
PES 1866 (15.9%) 141 (17.6%) 0.177 0.56
ZES 2866 (24.4%) 204 (25.6%) 0.332 0.36
EES 3640 (30.9%) 217 (27.2%) 0.027 –1.08
BES 1085 (9.2%) 56 (7.0%) 0.036 –0.98
Others 155 (1.3%) 12 (1.5%) 0.656 0.12
Stent diameter [mm] 3.2 ± 0.4 3.1 ± 0.4 < 0.001 –2.50
Stent length [mm] 26.1 ± 9.5 25.7 ± 8.9 0.327 –0.43
Number of stents 1.4 ± 0.8 1.5 ± 0.8 0.011 1.25
Values are mean ± standard deviation or number (%). The p values for continuous data were obtained from the analysis of the unpaired t-test. 
The p values for categorical data were obtained from the chi-square test. SD — standardized difference; LVEF — left ventricular ejection fraction; 
BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood pressure; STEMI — ST-segment elevation myocardial infarction; 
NSTEMI — non-STEMI; PCI — percutaneous coronary intervention; MI — myocardial infarction; CABG — coronary artery bypass grafting; 
CVA — cerebrovascular accidents; HF — heart failure; CPR — cardiopulmonary resuscitation; CK-MB — creatine kinase myocardial band;  
NT-proBNP — N-terminal pro-B-type natriuretic peptide; HDL — high-density lipoprotein; LDL — low-density lipoprotein; BBs — beta-blockers; 
ACEIs — angiotensin converting enzyme inhibitors; ARBs — angiotensin receptor blockers; CCBs — calcium channel blockers;  
ACC/AHA — American College of Cardiology/American Heart Association; SES — sirolimus-eluting stents; PES — paclitaxel-eluting stents; 
ZES — zotarolimus-eluting stents; EES — everolimus-eluting stents; BES — biolimus-eluting stents
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groups were evaluated using the unpaired t-test, 
and the data are expressed as the mean ± standard 
deviations. In case of categorical variables, the dif-
ferences between two groups were analyzed with 
the c2 test, or, if not applicable, the Fisher exact 
test, and data are expressed as counts and percent-
ages. Various clinical outcomes of this study were 
evaluated using the Kaplan-Meier method, and 
differences between two groups were compared 
using the log-rank test. Among the total covariates, 
only significant confounding covariates (p < 0.001 
or those having predictive values) were included 
when performing multivariate Cox regression 
analysis, as shown in Table 2. For all analyses, two-
sided p values < 0.05 were considered statistically 
significant [13].
Results
Baseline clinical, laboratory, angiographic, 
and procedural characteristics
The baseline, laboratory, angiographic, and 
procedural characteristics of the present study 
population are summarized in Table 1. The mean 
age of the patients in the female group was higher 
than that of the male group (68.3 ± 11.5 years vs. 
56.7 ± 11.2 years, p < 0.001). The average level of 
left ventricular ejection fraction (LVEF) was similar 
and well preserved between the two groups (52.6 ± 
± 11.0% vs. 52.5 ± 11.8, p = 0.724). The proportion 
of patients who had decreased LVEF (< 40%) was 
also similar between the two groups. The follow-
ing values were higher in the male group than in 
the female group: number of ST-segment elevation 
myocardial infarction (STEMI); mean value of body 
mass index, diastolic blood pressure; serum cre-
atinine level; triglyceride level; prescription rates 
of ASA, ticagrelor, prasugrel, beta-blockers, and 
lipid-lowering agents; and numbers of left anterior 
descending (LAD) artery as the infarct-related ar-
tery (IRA) or treated vessel; single-vessel disease; 
and the deployment of everolimus-eluting stents 
and biolimus-eluting stents. By contrast, the female 
group showed higher values than the male group for 
the following: number of non-STEMI; proportion 
of hypertension, DM, previous cerebrovascular 
accident (CVA), and HF; mean values of serum 
N-terminal pro-B-type natriuretic peptide, total 
cholesterol, high-density lipoprotein cholesterol, 
and low-density lipoprotein cholesterol; prescrip-
tion rates of clopidogrel; numbers of right coronary 
artery (RCA) as the IRA and treated vessel; ACC/ 
/AHA type C lesion; ≥ three-vessel disease; and 
number of deployed stent.
Clinical outcomes
Table 2 and Figure 2 show the clinical outcomes 
at 30 days, 1 year, and 2 years. During 1 month, 
the cumulative incidences of MACEs and all-cause 
death were significantly higher in the female 
group than in the male group. At 1 year after the 
index PCI, the cumulative incidences of MACEs, 
all-cause death, and Re-MI were also higher in 
the female group in the male group. Moreover, 
at 2 years, the cumulative incidences of all-cause 
death (adjusted hazard ratio [aHR]: 1.561; 95% 
confidence interval [CI]: 1.103–2.210; p = 0.012) 
and Re-MI (aHR: 1.800; 95% CI: 1.089–2.974; 
p = 0.022) were significantly higher in the female 
group than those in the male group. However, the 
cumulative incidences of ST, any repeat revascu-
larization, TLR, TVR, and non-TVR were similar 
between the two groups. 
Table 3 shows independent predictors for all-
cause death and Re-MI at 2 years. Figure 3 shows 
the subgroup analyses for MACEs. In cases of over 
40% of LVEF, non-hypertensive patients, ACC/ 
/AHA non-type C lesion, and patients who had non-
-RCA as IRA, who received lipid-lowering agents, 
and who currently smoke on admission showed 
worse outcomes for the female group compared 
with the male group in terms of MACEs.
Discussion
The main findings of the current study are as 
follows: 1) During 1 month, the cumulative inci-
dences of MACEs and all-cause death were signifi-
cantly higher in the female group than those in the 
male group; 2) At 1 year, the cumulative incidences 
of MACEs, all-cause death, and Re-MI were also 
higher in the female group than those in the male 
group; 3) At 2 years, the cumulative incidences 
of all-cause death and Re-MI were significantly 
higher in the female group than those in the male 
group; 4) However, the cumulative incidences of 
ST, any repeat revascularization, TLR, TVR, and 
non-TVR were similar between the two groups 
after adjustment.
To date, sex difference for MACEs and mor-
tality showed debatable results [16, 17]. Other 
studies have reported that women have smaller 
arterial diameter and lower sensitivity to cardiac 
function tests and receive a more suboptimal medi-
cal treatment compared with men [18–20]. In the 
present cohort, before risk adjustment, the female 
group had less favorable baseline characteristics 
for CVD risk factor profiles such as old age, higher 
proportions of hypertension, DM, previous history 
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of CVA, HF, cardiogenic shock, and smaller mean 
diameter of deployed stents and showed signifi-
cantly higher cumulative incidences of MACEs 
compared with the male group. These study results 
are consistent with the results of Bell’s and Nappi’s 
study [3]. The unfavorable effects of smoking on 
Table 2. Clinical outcomes by the Kaplan-Meier analysis and the Cox-proportional hazard ratio analysis 
up to 2 years.







HR (95% CI) P HR (95% CI) P
30 days
MACE 221 (1.9) 32 (4.0) < 0.001 2.155 (1.487–3.122) < 0.001 1.457 (1.021–2.216) 0.035
All-cause death 155 (1.3) 22 (2.8) 0.001 2.105 (1.347–3.289) 0.001 1.699 (1.074–2.687) 0.023
Cardiac death 145 (1.2) 19 (2.4) 0.006 1.942 (1.204–3.134) 0.007 1.505 (0.921–2.457) 0.102
Re-MI 47 (0.4) 6 (0.8) 0.133 1.896 (0.810–4.434) 0.140 1.806 (0.757–4.310) 0.183
Any revascularization 31 (0.3) 5 (0.6) 0.060 2.409 (0.937–6.196) 0.068 2.045 (0.865–3.374) 0.345
TLR 9 (0.1) 2 (0.3) 0.104 3.314 (0.716–15.34) 0.125 2.702 (0.539–13.56) 0.227
TVR 16 (0.1) 4 (0.5) 0.011 3.737 (1.249–11.18) 0.018 2.433 (0.990–8.502) 0.076
Non-TVR 14 (0.1) 1 (0.1) 0.951 1.066 (0.140–8.103) 0.951 1.131 (0.144–8.910) 0.907
ST (definite or probable)
Acute 10 (0.1) 0 (0.0) 0.410 — — — —
Subacute 29 (0.2) 3 (0.4) 0.483 1.342 (0.409–4.410) 0.627 1.031 (0.266–3.991) 0.965
Total 39 (0.3) 3 (0.4) 0.833 1.004 (0.310–3.249) 0.995 1.173 (0.322–4.264) 0.809
1 year
MACEs 660 (5.7) 70 (8.9) < 0.001 1.585 (1.239–2.028) < 0.001 1.402 (1.090–1.803) 0.009
All-cause death 245 (2.1) 35 (4.4) < 0.001 2.121 (1.489–3.023) < 0.001 1.660 (1.153–2.390) 0.006
Cardiac death 204 (1.7) 24 (3.0) 0.009 1.747 (1.144–2.666) 0.010 1.238 (0.831–1.980) 0.261
Re-MI 107 (0.9) 16 (2.1) 0.002 2.229 (1.318–3.770) 0.003 2.040 (1.189–3.501) 0.010
Any revascularization 340 (3.0) 23 (3.0) 0.980 1.005 (0.659–1.534) 0.980 0.974 (0.635–1.495) 0.905
TLR 97 (0.9) 7 (0.9) 0.857 1.073 (0.498–2.311) 0.857 1.011 (0.464–2.204) 0.978
TVR 166 (1.5) 12 (1.6) 0.812 1.072 (0.598–1.929) 0.812 1.048 (0.578–1.900) 0.877
Non-TVR 177 (1.6) 11 (1.5) 0.794 1.084 (0.590–1.994) 0.794 1.174 (0.636–2.176) 0.608
ST (definite or probable)
Late 35 (0.3) 4 (0.5) 0.316 1.885 (0.667–5.329) 0.232 1.343 (0.403–4.479) 0.631
Total (0–365 days) 74 (0.6) 7 (0.9) 0.397 1.372 (0.631–2.984) 0.424 1.116 (0.481–2.591) 0.799
2 years
MACEs 819 (7.2) 78 (10.0) 0.003 1.419 (1.125–1.790) 0.003 1.264 (1.001–1.598) 0.052
All-cause death 283 (2.5) 38 (4.8) < 0.001 1.988 (1.417–2.789) < 0.001 1.561 (1.103–2.210) 0.012
Cardiac death 224 (1.9) 25 (3.2) 0.016 1.654 (1.094–2.500) 0.017 1.216 (0.797–1.857) 0.364
Re-MI 142 (1.3) 18 (2.4) 0.010 1.885 (1.154–3.078) 0.011 1.800 (1.089–2.974) 0.022
Any revascularization 444 (4.0) 27 (3.6) 0.594 1.111 (0.754–1.639) 0.594 1.161 (0.785–1.717) 0.453
TLR 121 (1.1) 8 (1.1) 0.956 1.021 (0.499–2.087) 0.956 1.008 (0.471–1.982) 0.982
TVR 228 (2.1) 14 (1.9) 0.726 1.101 (0.642–1.889) 0.726 1.094 (0.626–1.864) 0.745
Non-TVR 223 (2.0) 13 (1.7) 0.602 1.160 (0.663–2.030) 0.602 1.273 (0.725–2.235) 0.400
ST (definite or probable)
Very late 15 (0.1) 1 (0.1) 0.988 1.021 (0.131–9.274) 0.684 1.042 (0.967–11.23) 0.280
Total (0–730 days) 89 (0.8) 8 (1.0) 0.445 1.104 (0.533–2.285) 0.790 1.207 (0.583–2.497) 0.613
*Adjusted by age, BMI, SBP, DBP, hypertension, diabetes, previous CVA, cardiogenic shock, NT-proBNP, total cholesterol, LDL cholesterol, 
clopidogrel, beta-blockers, lipid lowering agents, infarct-related artery (LAD and RCA), treated vessel (RCA), ≥ 3-vessel, stent diameter. HR — 
hazard ratio; CI — confidence interval; MACEs — major adverse cardiac events; Re-MI — re-myocardial infarction; TLR — target lesion revas-
cularization; TVR — target vessel revascularization; ST — stent thrombosis
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CAD include increasing plasma fibrinogen level, 
reducing high-density lipoprotein cholesterol level, 
increasing carboxyhemoglobin level, and increasing 
platelet stickiness and aggregation under the milieu 
of AMI [21, 22]. Furthermore, endothelial dysfunc-
tions, including reduced nitric oxide release [23] 
and inflammations [24], are involved in this process. 
In this study, the cumulative incidence of 
all-cause death, both early (30 days) and late 
(1 year and 2 year), and the cumulative incidence 
of Re-MI after 1 month of the index PCI, were 
higher in the female group than that in the male 
group after adjustment (Fig. 2). The possible 
explanation for these worse clinical outcomes in 
the female smokers’ group is related with the de-
creased estrogen activity or production [25]. Ad-
ditionally, a Danish report suggested that women 









































































Log-rank p = 0.003
Log-rank p < 0.001 Log-rank p = 0.010
Log-rank p = 0.445
aHR: 1.264; 95% CI: 1.001–1.598; p = 0.052
aHR: 1.561; 95% CI: 1.103–2.210; p = 0.012 aHR: 1.800; 95% CI: 1.089–2.974; p = 0.022















































































Figure 2. Kaplan-Meier Analysis for major adverse cardiac events (MACEs) (A), stent thrombosis (B), all-cause (C) and 
recurrent myocardial infarction (D); CI — confidence interval; aHR — adjusted hazard ratio.
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deleterious effects of smoking [6]. According to 
other studies [21, 26], women are more suscepti-
ble to the effects of nicotine consumption, which 
causes vasoconstriction, compared with men. 
Although previous studies [20, 27] have reported 
that less aggressive treatment of acute coronary 
syndrome may be a causative factor to poorer 
outcomes in women than in men, in this study, 
the proportions of primary PCI (92.5% vs. 91.7%, 
p = 0.508) and PCI within 24 h (78.0% vs. 75.8%, 
p = 0.354) were similar at baseline (Table 1). 
Moreover, both primary PCI and PCI within 24 h 
were not predictors of all-cause death and Re-MI 
in our study (Table 3).
In the GUSTO-1 trial, single-vessel disease 
was more frequently observed in smokers com-
pared with nonsmokers (63% vs. 55%) [28]. In the 
current study, singe-vessel disease was also more 
frequently observed compared with multivessel 
disease in both sexes (Table 1). It is highly likely 
that the mortality rate for RCA as an IRA is lower 
than for LAD [29]. Despite the number of RCA as 
an IRA was higher in the female group than that in 
the male group (47.2% vs. 43.7%, p = 0.039), all- 
-cause death was significantly higher in the female 
group than that in the male group after adjustment. 
Hence, sex difference for the major clinical out-
comes was strongly suggested in this cohort study.
Figure 3. Subgroup analyses for major adverse cardiac events (MACEs). CI — confidence interval; LVEF — left ven-
tricular ejection fraction; ACC/AHA — American College of Cardiology/American Heart Association; LAD — left an-
terior descending coronary artery; RCA — right coronary artery; IRA — infarct-related artery; STEMI — ST-segment 
elevation myocardial infarction.
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Approximately 23% of patients who quit smok-
ing at 30 days had relapsed at 12 months [30]. One 
Asian study showed that a total of 34.1% of smok-
ers continued to smoke or relapsed after a period 
of time of quitting smoking [31]. Therefore, it can 
be assumed that greater than 30% of the enrolled 
patients continued to smoke after the index PCI 
during the follow-up period.
In the present cohort study, the proportion of 
women was relatively smaller compared to the 
total number of men (93.6% vs. 6.4%). This pro-
portional difference of enrolled patients between 
the two groups is consistent with the previous 
studies [32, 33]. In the previous studies, the 
number of smokers is relatively lower in women 
than in men with some regional variations, spe-
cifically in Asian regions where the prevalence 
of women smoking is less than 10% [32, 33]. 
Moreover, the KAMIR is a nationwide, prospec-
tive, observational multicenter registry in South 
Korea, and more than 50 high-volume university 
or community hospitals participated in this study 
[7, 8]. Therefore, we believe that in this study, 
the study population is not small for providing 
reasonably accurate results.
Limitations of the study
This study has the following limitations. 
First, due to the characteristics of the nonrand-
omized retrospective nature of the study, there 
may be some incomplete variables. Second, the 
smoking status of the study population was as-
sessed on admission, and the registry data did not 
include full detailed data concerning the status of 
smoking including before admission and during 
the follow-up period [9, 13]. Therefore, these 
factors may contribute bias. Third, this study 
assessed the discharge medications. Fourth, it 
was not possible to compare the initial laboratory 
results with the serial follow-up results because 
of the limited registry data, subsequently intro-
ducing bias. Fifth, although multivariate Cox 
proportional regression analysis was performed, 
the results of the present study are relatively 
different according to the variables included or 
excluded when performing this analysis. Sixth, 
the strategy of antiplatelet therapy (e.g., dual 
antiplatelet therapy or TAPT) was left to the phy-
sician’s discretion, which may have influenced 
the major clinical outcomes [9]. Finally, AMI 
was defined according to the current guidelines 
including the 3rd universal definition of MI [11, 
12] in this study. However, the fourth universal 
definition of MI [34] contains more updated and 
accurate diagnostic criteria than those of the 
third universal definition of MI.
Conclusions
In conclusion, the female group showed worse 
short-term and long-term clinical outcomes com-
pared with the male group comprising Korean 
AMI patients with history of current smoking who 
underwent successful DES implantation. However, 
additional studies are required to determine the 
clinical implications of these results.
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